Less than 10% of people that would benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it releases its initial advice on the medications.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.
Per projections, over two billion are projected to be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be treated with comprehensive and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major barriers to widespread access to the jabs that can assist patients in reducing significant body mass, notes the agency.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the supply of these medications would only suffice for approximately 100 million people – under 10% of the global need, as stated by the health organization.
The guideline calls on governments and firms to expand availability, by measures like voluntary licensing.
Exclusive production rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Injections Operate
The injections imitate a biological compound to delay gastric emptying, reduce hunger and increase feelings of fullness so people eat less.
Individuals commonly see weight reduction within a few weeks of starting on the once-weekly jabs.
Research suggests people may see weight return after a year of halting the drug, as their usual food cravings resume.
To be above a healthy weight raises your chance for contracting diseases, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns individuals in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
